ABCAM PLC Transaction complete between Abcam and Expedeon (3972Y)

TIDMABC

RNS Number : 3972Y

ABCAM PLC

02 January 2020

2 January 2020

ABCAM PLC

("Abcam" or "the Group")

Completion of transaction between Abcam and Expedeon

Abcam plc (AIM LSE: ABC), a global leader in the supply of life science research tools, today announces that the transaction to acquire Expedeon Ltd, Innova Biosciences Ltd. and TGR BioSciences (the "Proteomics and Immunology business") from Expedeon AG ("Expedeon") (the "Acquisition") has now completed.

As announced in November 2019, the Acquisition secures a complementary portfolio of leading protein conjugation technologies and products for Abcam, including well-known industry brands Lightning-Link(R) and CaptSure(TM) .

Commenting on the completion of the Acquisition, Alan Hirzel, CEO of Abcam, said:

"We are delighted to have completed this transaction and welcome our new colleagues to Abcam. Expedeon's portfolio of products and technology, combined with Abcam's antibody and protein strengths, place us well to address the growing need for antibody conjugation and multiplexing solutions."

Ondra LLP provided advice to the Board of Directors of Abcam in relation to this transaction.

For further information, please contact:

Abcam

+ 44 (0) 1223 696 000

Alan Hirzel, Chief Executive Officer

Gavin Wood, Chief Financial Officer

James Staveley, VP Investor Relations

J.P. Morgan Cazenove - Nominated Advisor and Joint Corporate Broker

[phone]

James Mitford / Hemant Kapoor

Numis - Joint Corporate Broker

[phone]

Garry Levin / Duncan Monteith

FTI Consulting (Media enquiries)

[phone]

Ben Atwell / Natalie Garland-Collins

Ondra LLP, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting solely for the Board of Directors of Abcam and no one else in connection with the matters described in this announcement and will not be responsible to anyone other than the Board of Directors of Abcam for providing the protections afforded to clients of Ondra LLP, nor for providing advice in relation to this announcement. Neither Ondra LLP nor any of its respective subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Ondra LLP in connection with this announcement or any matter referred to herein.

Forward looking statements

This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam Group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam Group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements. The Abcam Group does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law.

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.

With eleven sites globally, many of Abcam's 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRBGBDDSBXBGCB

(END) Dow Jones Newswires

January 02, 2020 02:00 ET (07:00 GMT)